Latest Treatment of schizophrenia Stories
TITUSVILLE, N.J., April 11, 2011 /PRNewswire/ -- The U.S. Food and Drug Administration (FDA) on April 6 approved INVEGAÂ® (paliperidone) extended-release tablets for the treatment of schizophrenia in adolescents 12 to 17 years of age.
BEERSE, Belgium, April 4, 2011 /PRNewswire/ -- Janssen EMEA -- New data from an independent prospective study presented last week at the 19th European Congress of Psychiatry (EPA 2011) shows treatment with RisperdalÂ® ConstaÂ® (risperidone long-acting injection (RLAI)) is associated with a lower risk of hospitalisation in patients with schizophrenia compared to treatment with other antipsychotics over a 12-month period.
In a major advance for schizophrenia research, an international team of scientists led by the University of California, San Diego School of Medicine and involving Trinity College Dublin researchers has identified a gene mutation strongly linked to schizophrenia that may be an important new target for the development of drug therapies.
Patients with schizophrenia who take antipsychotic medications appear to lose a small but measurable amount of brain tissue over time.
ORLANDO, Fla., Nov. 19, 2010 /PRNewswire/ -- Schizophrenia is a chronic and disabling brain disorder that affects 1 percent of the U.S. population and results in substantial medical and societal costs, in particular from use of health-care resources.
SAN DIEGO, Nov. 17, 2010 /PRNewswire/ -- It's estimated that about 275,000 people in California, including 9,500 people in San Diego, are diagnosed with schizophrenia, a chronic and often disabling brain disorder.
The potential for harmful side effects associated with anti-psychotic medications for treating schizophrenia is a frustration for mental-health professionals who must balance this with the positive benefits of drugs.
CME Outfitters Announces New neuroscienceCME Webcast: "Advances in the Treatment of Schizophrenia: New Approaches" Offered as a simultaneous webcast and telephone audioconference premiering Tuesday, November 16, 2010, from 12:00 p.m.-1:30 p.m.
NEW YORK, July 29 /PRNewswire/ -- Intra-Cellular Therapies, Inc. today announced the results from a Phase Ib/II clinical trial in patients with schizophrenia with ITI-007, the Company's unique, investigational new drug for the treatment of schizophrenia.
TITUSVILLE, N.J., May 24 /PRNewswire/ -- According to a new survey sponsored by Janssen,Â® Division of Ortho-McNeil-Janssen Pharmaceuticals, Inc, 80 percent of patients with schizophrenia, a chronic, severe and disabling brain disorder, say their psychiatrists do well or very well in treating them with courtesy and respect.